JP6234466B2 - 予測因子を用いて同定された患者サブ集団における癌の処置のためのマシチニブの使用 - Google Patents

予測因子を用いて同定された患者サブ集団における癌の処置のためのマシチニブの使用 Download PDF

Info

Publication number
JP6234466B2
JP6234466B2 JP2015535036A JP2015535036A JP6234466B2 JP 6234466 B2 JP6234466 B2 JP 6234466B2 JP 2015535036 A JP2015535036 A JP 2015535036A JP 2015535036 A JP2015535036 A JP 2015535036A JP 6234466 B2 JP6234466 B2 JP 6234466B2
Authority
JP
Japan
Prior art keywords
pain
masitinib
gemcitabine
treatment
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015535036A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015532296A5 (enExample
JP2015532296A (ja
Inventor
モウッシー，アライン
キネト，ジーン‐ピエール
ピクエマル，デイビッド
Original Assignee
エービー サイエンス
エービー サイエンス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エービー サイエンス, エービー サイエンス filed Critical エービー サイエンス
Publication of JP2015532296A publication Critical patent/JP2015532296A/ja
Publication of JP2015532296A5 publication Critical patent/JP2015532296A5/ja
Application granted granted Critical
Publication of JP6234466B2 publication Critical patent/JP6234466B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2015535036A 2012-10-04 2013-10-04 予測因子を用いて同定された患者サブ集団における癌の処置のためのマシチニブの使用 Active JP6234466B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306214 2012-10-04
EP12306214.3 2012-10-04
PCT/EP2013/070741 WO2014053650A1 (en) 2012-10-04 2013-10-04 Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors

Publications (3)

Publication Number Publication Date
JP2015532296A JP2015532296A (ja) 2015-11-09
JP2015532296A5 JP2015532296A5 (enExample) 2016-11-10
JP6234466B2 true JP6234466B2 (ja) 2017-11-22

Family

ID=47073382

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015535036A Active JP6234466B2 (ja) 2012-10-04 2013-10-04 予測因子を用いて同定された患者サブ集団における癌の処置のためのマシチニブの使用

Country Status (20)

Country Link
US (1) US10238649B2 (enExample)
EP (1) EP2903616B8 (enExample)
JP (1) JP6234466B2 (enExample)
KR (1) KR102149483B1 (enExample)
CN (1) CN104968347A (enExample)
AR (1) AR092899A1 (enExample)
AU (1) AU2013326463B2 (enExample)
BR (1) BR112015007144A2 (enExample)
CA (1) CA2886979C (enExample)
DK (1) DK2903616T3 (enExample)
EA (1) EA037368B1 (enExample)
ES (1) ES2656640T3 (enExample)
IL (1) IL238107B (enExample)
MX (1) MX369999B (enExample)
NZ (1) NZ706420A (enExample)
SG (1) SG11201502626PA (enExample)
SI (1) SI2903616T1 (enExample)
TW (1) TWI609686B (enExample)
WO (1) WO2014053650A1 (enExample)
ZA (1) ZA201503054B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160244845A1 (en) * 2013-10-04 2016-08-25 Ab Science Method for determining the prognosis of pancreatic cancer
MX2016014574A (es) * 2014-05-08 2017-02-23 Oncoethix Gmbh El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo.
TW201615222A (zh) * 2014-10-24 2016-05-01 朗齊生物醫學股份有限公司 免疫疾病用藥臨床新應用
EP3280448B1 (en) 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
RS62108B1 (sr) 2016-03-02 2021-08-31 Eisai R&D Man Co Ltd Antitelo-lek konjugati na bazi eribulina i postupci primene
NZ745778A (en) * 2016-03-25 2022-07-01 Ab Science Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
CN107267454B (zh) * 2016-04-07 2025-05-23 内蒙古原生元生物科技有限公司 一种脐血nk细胞的体外扩增方法及其试剂盒与应用
AU2018209164B2 (en) 2017-01-17 2021-11-04 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN110381938A (zh) * 2017-02-01 2019-10-25 大连万春布林医药有限公司 减少中性粒细胞缺乏症的方法
CN118903436A (zh) 2018-01-31 2024-11-08 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
US20210398672A1 (en) * 2018-10-29 2021-12-23 Northwestern University Big Data-Driven Personalized Management of Chronic Pain
WO2020115108A1 (en) * 2018-12-06 2020-06-11 Sørlandet Sykehus Hf Egfr inhibitors and their use in the treatment of neuroathic pain
WO2020115261A1 (en) * 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
SMT202400484T1 (it) 2019-12-30 2025-01-14 Deciphera Pharmaceuticals Llc Composizioni di 1-(4-bromo-5-(1-etil-7-(metilammino)-2-osso-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofenil)-3-fenilurea
CN114214396A (zh) * 2020-06-30 2022-03-22 宁波市康宁医院(宁波市精神疾病预防控制中心、宁波市微循环与莨菪类药研究所) Gabrd甲基化作为抗海洛因复吸靶点的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8450302B2 (en) * 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
MXPA05001277A (es) 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
WO2007015935A2 (en) 2005-07-29 2007-02-08 Bayer Healthcare Llc Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
US20100143935A1 (en) 2006-12-01 2010-06-10 Apocell, Inc. c-KIT Phosphorylation in Cancer
JP2010515708A (ja) 2007-01-12 2010-05-13 アブ サイエンス 代謝拮抗薬およびチロシンキナーゼ阻害剤を用いた固形癌の併用治療
SI2118099T1 (sl) 2007-02-13 2011-11-30 Ab Science Postopek za sintezo 2-aminotiazolnih spojin kot kinaznih inhibitorjev
WO2011056963A1 (en) 2009-11-04 2011-05-12 The University Of North Carolina At Chapel Hill Methods and compositions for predicting survival in subjects with cancer
AR080096A1 (es) 2010-02-01 2012-03-14 Ab Science Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib
WO2012170640A1 (en) * 2011-06-07 2012-12-13 The Trustees Of Columbia University In The City Of New York Methods and compositions for trail-drug combination therapy

Also Published As

Publication number Publication date
CA2886979C (en) 2021-01-05
TW201414475A (zh) 2014-04-16
MX2015004264A (es) 2015-10-12
EP2903616A1 (en) 2015-08-12
WO2014053650A1 (en) 2014-04-10
KR20150092739A (ko) 2015-08-13
CN104968347A (zh) 2015-10-07
EP2903616B8 (en) 2018-02-07
SG11201502626PA (en) 2015-05-28
JP2015532296A (ja) 2015-11-09
US20150272945A1 (en) 2015-10-01
AU2013326463B2 (en) 2018-01-18
EA201500373A1 (ru) 2016-02-29
EA037368B1 (ru) 2021-03-19
EP2903616B1 (en) 2017-12-13
AR092899A1 (es) 2015-05-06
US10238649B2 (en) 2019-03-26
ES2656640T3 (es) 2018-02-27
CA2886979A1 (en) 2014-04-10
BR112015007144A2 (pt) 2017-12-12
TWI609686B (zh) 2018-01-01
MX369999B (es) 2019-11-28
IL238107B (en) 2018-03-29
AU2013326463A1 (en) 2015-04-16
ZA201503054B (en) 2016-11-30
DK2903616T3 (da) 2018-01-29
NZ706420A (en) 2018-08-31
SI2903616T1 (en) 2018-02-28
KR102149483B1 (ko) 2020-08-28

Similar Documents

Publication Publication Date Title
JP6234466B2 (ja) 予測因子を用いて同定された患者サブ集団における癌の処置のためのマシチニブの使用
Jiang et al. Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study
Hata et al. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection
US20160199399A1 (en) Methods for predicting drug responsiveness in cancer patients
CA2850175C (en) Biomarkers for predicting sensitivity to cancer treatments
EP2744494A1 (en) Combination cancer therapy of hsp90 inhibitor with antimetabolite
KR20150131312A (ko) 마이크로rna 및 egfr-tki 억제제를 이용한 조합 암 치료
US9334500B2 (en) Methods and pharmaceutical compositions for treating cancer
US20160208328A1 (en) Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
US20210047695A1 (en) Cancer treatments and methods of selecting same
KR20250055443A (ko) Cdk4/6 저해제에서 진행된 er+ 유방암의 라소폭시펜 병용 치료
Zhu et al. Personalized medicine for glioblastoma: current challenges and future opportunities
US20200316067A1 (en) Combination of raf inhibitors and taxanes
Nazarov et al. Effects of n-Myc and c-Myc on the expression of p53 family members and their transcriptional targets in human neuroblastoma cells
US20250179584A1 (en) Precision therapy for the treatment of cancer
Verma et al. Targeting Epigenetic Regulators in Cancer to Overcome Resistance to Targeted Therapy
WO2013103795A1 (en) Bis (thiohydrazide amide) compounds for treating cancers
Sung11 et al. Yung-Sung Yeh1, 2, 3, Hsiang-Lin Tsai2, 4, 5, 6, Ching-Wen Huang2, 5, 7, Jui-Ho Wang8, Yi-Wen Lin9, Hsiu-Chih Tang10

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160923

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160923

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170913

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171017

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171024

R150 Certificate of patent or registration of utility model

Ref document number: 6234466

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250